Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial,The Lancet Haematology

当前位置： X-MOL 学术 › Lancet Haematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
The Lancet Haematology ( IF 15.4 ) Pub Date : 2024-09-06 , DOI: 10.1016/s2352-3026(24)00249-7
Gordon Cook ₁ , A John Ashcroft ₂ , Ethan Senior ₃ , Catherine Olivier ₃ , Anna Hockaday ₃ , Jeanine Richards ₃ , Jamie D Cavenagh ₄ , John A Snowden ₅ , Mark T Drayson ₆ , Ruth de Tute ₇ , Lesley Roberts ₈ , Roger G Owen ₇ , Kwee Yong ₉ , Mamta Garg ₁₀ , Kevin Boyd ₁₁ , Hamdi Sati ₁₂ , Sharon Gillson ₃ , Mark Cook ₁₃ , David A Cairns ₃ , Christopher Parrish ₁ ,

Affiliation

Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Mid-Yorkshire NHS Trust, Wakefield, UK.
Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Department of Haematology, Barts Health NHS Trust, London, UK.
Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK.
Leek, UK.
University College London Hospitals, NHS Foundation Trust, London, UK.
Leicester Royal Infirmary, Leicester, UK.
Department of Haematology, Royal Marsden Hospital, London, UK.
Department of Haematology, Singleton Hospital, Swansea, UK.
Bristol-Myers Squibb, Boudry, Switzerland.

The efficacy of consolidation and maintenance in the context of salvage autologous haematopoietic stem-cell transplantation (HSCT) for relapsed multiple myeloma remains unclear. We aimed to assess whether consolidation after salvage autologous HSCT, using ixazomib, thalidomide, and dexamethasone, followed by maintenance with single agent ixazomib is superior to observation.

中文翻译：

伊沙佐米作为巩固和维持治疗与观察治疗符合挽救性自体干细胞移植条件的复发性多发性骨髓瘤患者（骨髓瘤 XII [ACCoRD]）：一项多中心、开放标签、随机、3 期试验的中期分析

在挽救性自体造血干细胞移植（HSCT）的情况下，巩固和维持对复发性多发性骨髓瘤的疗效仍不清楚。我们旨在评估使用伊沙佐米、沙利度胺和地塞米松挽救性自体 HSCT 后，然后使用伊沙佐米单药维持治疗后巩固是否优于观察。

更新日期：2024-09-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文